Stockwinners Market Radar for February 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:05 EST First National Corporation announces 17% increase in cash dividend - The Board of Directors of First National declared a quarterly cash dividend of 14c per share on February 9. This was a 17% increase compared to the quarterly dividend paid on December 10, 2021. The dividend is payable on March 11, 2022 to shareholders of record as of February 25.

16:02 EST AGNC Investment reports estimated tangible net book value of $14.91 per share - The company announced its estimated tangible net book value of $14.91 per common share as of January 31. The estimate of tangible net book value includes a deduction for the company's January dividend of12c per common share, which was declared on January 10 with a January 31 record date.

15:53 EST Eli Lilly 'disappointed' with outcome of ODAC meeting on sintilimab - Lilly issued the following statement on the sintilimab Oncologic Drugs Advisory Committee, or ODAC, Meeting: "While we are disappointed with the outcome of today's ODAC as it relates to the investigational product sintilimab, we appreciated the opportunity to publicly discuss the application and broader issues related to single-country clinical trials. We had hoped that sintilimab could have played a positive role for patients and the U.S. healthcare system through an aggressive pricing strategy. We acknowledge that the landscape has changed dramatically on a number of fronts since the ORIENT-11 study was conducted and the sintilimab application was initiated. Lilly wholeheartedly agrees with the importance of ethics in clinical trial conduct and clinical trial diversity. We have long-standing initiatives in place to advance diversity and inclusion in Lilly-conducted clinical trials. Along with Innovent, we will continue to work with the FDA as it completes its review of the sintilimab application. Lilly remains committed to bringing forward medicines with the potential to meaningfully improve treatment paradigms for patients with cancer." Reference Link

15:39 EST Astra Space trading resumes

15:31 EST Cornerstone Building trading resumes

15:23 EST Affirm confirms 'small portion' of Q2 results tweeted early due to 'human error' - Affirm stated on its corporate Twitter account: "Due to human error, a small portion of Affirm's fiscal Q2 results were inadvertently tweeted from Affirm's official Twitter account earlier today. Affirm has since issued its complete fiscal Q2 results". Reference Link

15:07 EST Radius Health granted additional orphan designation for cannabidiol - The FDA granted Radius Health orphan status for cannabidiol as treatment of chromosome 15q11.2-13.1 duplication syndrome, according to a post to the agency's website. Reference Link

15:04 EST Affirm falls over 28% after giving Q3, FY22 guidance - Trading in the stock was briefly halted.

14:56 EST Affirm sees Q3 revenue $325M-$335M, consensus $330.07M - Sees Q3 GMV of $3.61B-$3.71B, revenue less transaction costs of $138M-$143M and adjusted operating loss as a percentage of revenue of (21) to (19)%.

14:54 EST Affirm reports active merchants increased to 168,000, active consumers grew 150% - Affirm reports active merchants increased from 8,000 to 168,000, driven primarily by the adoption of Shop Pay Installments by merchants on Shopify's platform. Active consumers grew 150% to 11.2 million and increased by 2.5 million, or 29%, compared to the period ended September 30, 2021. Transactions per active consumer increased 15% to 2.5 as of December 31, 2021. "Affirm's strong growth accelerated this quarter, reflecting the key advantages of our superior technology, and commitment to putting people first. We more than doubled gross merchandise volume year over year. Over the last 12 months, we have added nearly seven million active consumers to our network, while enabling 168,000 merchant partners to better serve their customers. Millions of people see Affirm as a smart way to pay because of our honest, transparent, and customizable payment terms. Merchants recognize our ability to help them drive growth and deliver the experience consumers are demanding at checkout. We remain focused on extending our lead as we scale enterprise partnerships and benefit from self-reinforcing network effects. With our talented team of Affirmers, we have never been more excited to expand the impact of our mission," said Max Levchin, Founder and CEO of Affirm.

14:29 EST Amazon's Wondery reaches exclusive licensing deal for NPR's 'How I Built This' - Amazon Music's Wondery announced an exclusive licensing deal for NPR's chart-topping podcast How I Built This, conceived by Guy Raz, who also hosts the program. New episodes of How I Built This will drop twice a week on Amazon Music and Wondery+ one week early, and will stream ad-free for Wondery+ and Amazon Music Unlimited subscribers and Prime members. How I Built This will continue to be available for fans to stream on all podcast services after the one-week exclusive window, and on the radio as usual. In the deal, Wondery has exclusive commercial ad sales rights, as well as the rights to YouTube distribution for video simulcasts. NPR will retain radio distribution and underwriting. "NPR and Guy Raz have built an extremely successful podcast and fanbase with How I Built This and we are excited to bring the show one week early for our listeners," said CEO of Wondery, Jen Sargent. "We are thrilled to announce this strategic collaboration and continue to bring customers around the world even more innovative, popular content with dynamic creators." Reference Link

13:04 EST Apple says advancements coming to AirTag 'with safety and privacy in mind' - Apple issued an update on AirTag and unwanted tracking on its website, stating in part: "Since AirTag's launch last April, users have written in to share countless stories of AirTag being instrumental in reuniting them with the things they value... AirTag was designed to help people locate their personal belongings, not to track people or another person's property, and we condemn in the strongest possible terms any malicious use of our products. Unwanted tracking has long been a societal problem, and we took this concern seriously in the design of AirTag. It's why the Find My network is built with privacy in mind, uses end-to-end encryption, and why we innovated with the first-ever proactive system to alert you of unwanted tracking... We've become aware that individuals can receive unwanted tracking alerts for benign reasons, such as when borrowing someone's keys with an AirTag attached, or when traveling in a car with a family member's AirPods left inside. We also have seen reports of bad actors attempting to misuse AirTag for malicious or criminal purposes... Apple has been working closely with various safety groups and law enforcement agencies. Through our own evaluations and these discussions, we have identified even more ways we can update AirTag safety warnings and help guard against further unwanted tracking... We design our products to provide a great experience, but also with safety and privacy in mind. Across Apple's hardware, software, and services teams, we're committed to listening to feedback and innovating to make improvements that continue to guard against unwanted tracking." Reference Link

12:01 EST Lumen falls -16.0% - Lumen is down -16.0%, or -$2.06 to $10.77.

12:01 EST Bowlero rises 18.1% - Bowlero is up 18.1%, or $1.40 to $9.12.

12:00 EST IronNet rises 28.5% - IronNet is up 28.5%, or $1.00 to $4.51.

11:52 EST Uber trading resumes

11:45 EST Homology Medicines to present on HMI-203 gene therapy candidate - Homology Medicines announced multiple presentations on HMI-203 gene therapy candidate for the treatment of Hunter syndrome, which is being evaluated in juMPStart, a Phase 1 open-label, dose-escalation clinical trial in adults with Hunter syndrome. In oral platform presentations, key eligibility criteria and planned endpoints for the juMPStart trial were discussed and data from the HMI-203 IND-enabling studies were presented. Homology also shared patient, caregiver and key opinion leader feedback on the unmet medical need in Hunter syndrome, despite the availability of enzyme replacement therapy , and the potential for a one-time gene therapy for patients that could impact peripheral and central nervous system manifestations. These presentations at the 18th Annual WORLDSymposium Meeting also included data on Homology's AAVHSC platform and potential to treat additional lysosomal storage disorders, including metachromatic leukodystrophy, based on CNS transduction in non-human primates. In the platform presentation titled, "Clinical Trial Design for HMI-203 Investigational Gene Therapy for Mucopolysaccharidosis Type II Informed by Cross-Correction Potential and Key Opinion Leader Input," new details about the juMPStart trial were presented along with data from IND-enabling studies, including: juMPStart clinical trial design, which includes three sequential dose cohorts with up to three adults with Hunter syndrome currently on ERT in each cohort; Select eligibility criteria and planned endpoints for juMPStart; and Evidence of cellular cross-correction indicating that I2S enzyme can be produced from transduced cells, secreted into the bloodstream and then taken up by nearby un-transduced cells following a single intravenous administration of HMI-203 in the Hunter syndrome murine model. Related, in the platform presentation and accompanying poster titled, "Summary of Nonclinical Data for a Gene Therapy Developmental Candidate HMI-203 for Mucopolysaccharidosis Type II, or Hunter Syndrome," additional data from IND-enabling studies with HMI-203 were presented. A single I.V. administration of HMI-203 in the Hunter syndrome murine model resulted in long-term: Transduction and therapeutically relevant I2S expression in key peripheral tissues and CNS; Reduction of LAMP1 accumulation in peripheral tissues and the CNS, which indicates normal lysosome function; Reduction in additional Hunter syndrome biomarkers; and Direct skeletal benefit by preventing progression of craniofacial and hindlimb deformities. In a poster co-authored with the National MPS Society, "Patient and Physician Perspectives Inform Clinical Trial Design for a Single Intravenous Dose of HMI-203, a Gene Therapy Candidate for Adults with Mucopolysaccharidosis Type II, or Hunter Syndrome," data on unmet medical need in adult patients with Hunter syndrome were highlighted alongside KOL feedback on the proposed juMPStart clinical trial design. Feedback from patients, caregivers and KOLs demonstrated that: While ERT is currently the most beneficial therapy for Hunter syndrome, the unmet medical needs remain high and most burdensome, including: limited range of motion and mobility, pain and hearing loss; Patient expectations for a one-time gene therapy, include disease maintenance with ERT-independence; and KOLs supported planned design for juMPStart, including ERT-discontinuation plan. Lastly, in the poster titled, "AAVHSCs and CNS-Targeting Gene Therapy for Lysosomal Storage Disorders," the potential of utilizing AAVHSCs for lysosomal storage disorders was presented. Following a single I.V. administration of AAVHSCs in NHPs, data demonstrated: Broad peripheral microglia tropism to cells that are important for maintaining CNS health;crossing of the blood-brain and -retina barriers, allowing access to the CNS; and Cross-correction potential of lysosomal enzymes in nearby cells.

11:35 EST Uber sees generating $5B in adjusted EBITDA by FY24

11:33 EST Uber sees turning free cash flow positive by end of year - Sees "strong" free cash flow generation by 2024.

11:33 EST Uber expects revenues to outpace gross bookings growth for FY21-FY24

11:31 EST 22nd Century secures USDA organic certification for Needle Rock farms - 22nd Century Group announced that is has received USDA Organic Certification under 7 CFR Part 205 for its hemp production at Needle Rock Farms. USDA Organic Certification will allow 22nd Century to command a premium price and margin for its hemp biomass, 22nd Century said in a statement. "Organic certification is a valuable asset that enables premium pricing for the biomass grown at our Needle Rock Farms location. It also expands our capabilities to create disruptive hemp/cannabis plant lines tailored to the most exacting customer requirements at a fraction of the time and cost of traditional breeding methods," says James A. Mish, CEO of 22nd Century Group. "Similar to the work done in order to commercialize other major crop lines, our disruptive hemp/cannabis plant lines can be tailored to express consistent levels of desirable major and minor cannabinoids, improved structural characteristics, heightened disease resistance and other key traits necessary for the economic and predictable production at commercial scale."

11:27 EST Uber seeing 'very constructive' trends in Mobility in U.S.

11:26 EST Ardelyx announces Appeal Denied Letter from FDA over CRL for tenapanor - In a regulatory filing earlier, Ardelyx disclosed that on February 4, the company received an Appeal Denied Letter from the Office of Cardiology, Hematology, Endocrinology and Nephrology, or "OCHEN," of the U.S. Food and Drug Administration in response to its Formal Dispute Resolution Request submitted in early December 2021, and following its submission on January 7, 2022, of additional clarifying data requested by OCHEN. "The company intends to appeal the ADL to the Office of New Drugs, Center for Drug Evaluation and Research. If accepted for consideration, the Company expects a decision on the appeal to the OND in April 2022," Ardelyx stated. The company submitted the FDRR in response to the Complete Response Letter, or "CRL," the company received on July 28, 2021, regarding its New Drug Application for the control of serum phosphorus in chronic kidney disease patients on dialysis. "The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor. The CRL noted that in order for the NDA to be approved, the company needs to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in CKD patients on dialysis. The ADL provided the company a potential additional path forward involving the resubmission of the NDA (without conducting an additional trial) with a number of new analyses of each of the company's Phase 3 clinical trials; an assessment of tenapanor's benefits and risks; and a proposal of how to label tenapanor for prescribers," Ardelyx stated.

11:15 EST Cassava Sciences citizens petition denied by FDA - A letter dated February 10 from the FDA to Jordan Thomas of Labaton Sucharow from Patrizia Cavazzoni, Director of the Center for Drug Evaluation and Research of the FDA, stated in part: "This letter responds to your citizen petition received on August 23, 2021, with supplements... [which describe] "grave concerns about the quality and integrity of the laboratorybased studies surrounding this drug candidate and supporting the claims for its efficacy," and requests that the Food and Drug Administration halt the current clinical studies of Simufilam sponsored by Cassava Sciences [and] oversee third party reanalysis of all clinical biomarker studies of Simufilam in Alzheimer's disease... We take the issues you raise seriously. Please note that your Petitions are being denied solely on the grounds that your requests are not the appropriate subject of a citizen petition. This response does not represent a decision by the Agency to take or refrain from taking any action relating to the subject matter of your Petitions." In morning trading after the letter was disclosed, shares of Cassava Sciences are off their best levels but remain up $6.98, or 14%, to $56.20. Reference Link

11:02 EST United Fire Group general counsel Neal Scharmer to retire - United Fire Group announced that Neal Scharmer, VP, General Counsel and Corporate Secretary, will retire from UFG on March 31, 2022, after more than 40 years practicing law, and having served in his current role for more than 20 years. UFG also announced the promotion of Sarah Madsen as Chief Legal Officer, effective March 31, 2022, upon the retirement of Mr. Scharmer. Ms. Madsen will oversee UFG's legal, regulatory, governance, compliance and vendor management matters. Ms. Madsen is an experienced attorney and leader, having served as corporate counsel and a partner of a Twin Cities litigation firm before she joined UFG as Assistant General Counsel in 2018.

10:58 EST Kohl's responds to director nominations from Macellum Advisors - Kohl's Corporation issued a statement regarding Macellum Advisors GP, LLC's announcement of its nomination of directors for election to the Kohl's Board of Directors at the company's 2022 Annual Meeting of Shareholders. "Kohl's believes Macellum's effort to take control of the Board is unjustified and counterproductive. Kohl's appointed two of Macellum's designees, along with an additional mutually agreed upon designee, to its Board pursuant to the 2021 settlement agreement with Macellum and certain other shareholders. All members of the Kohl's Board, other than its CEO, are independent. Macellum's claim that Kohl's Board is not equipped to evaluate sale opportunities is groundless. The Board designated its Finance Committee, which is comprised entirely of independent directors, was formed pursuant to the settlement with Macellum and includes one of Macellum's 2021 designees, to lead the review of any expressions of interest. Additionally, the Company and the Board have engaged financial advisors, including Goldman Sachs and PJT Partners, and have asked Goldman Sachs to engage with interested parties. Furthermore, Macellum's claim to be "disappointed and shocked" by Kohl's rejection of the previously disclosed expressions of interest is disingenuous. Macellum has on multiple occasions stated publicly that Kohl's is worth "at least $100 per share." Furthermore, Macellum's claim to be "disappointed and shocked" by Kohl's rejection of the previously disclosed expressions of interest is disingenuous. Macellum has on multiple occasions stated publicly that Kohl's is worth "at least $100 per share." Finally, Macellum's comments on the Board's adoption of a limited-duration shareholder rights plan are misleading. The Board adopted the rights plan to protect shareholder value by ensuring that the Board can conduct an orderly review of any expressions of interest and by preventing any person or group from gaining control of Kohl's through open market accumulation. As we previously announced, based on our performance in 2021, we are positioned to exceed our key 2023 financial goals two years ahead of plan. We are optimistic about significant value creation in both the near and long term as a result of our transformational strategy."

10:57 EST Kohl's: Macellum's effort to take control of board 'unjustified'

10:42 EST Correct: Lockheed Martin sees Q1 headwind in Space unit $450M, $300M at RMS

10:29 EST City of Hagerstown partners with InvoiceCloud - The City of Hagerstown, MD, has partnered with InvoiceCloud, to launch an enhanced digital payment portal for over 40,000 Hagerstown residents. The new payment portal, powered by InvoiceCloud, launched on January 31.

10:27 EST Lockheed Martin sees Q1 revenue down $750M-$1B y/y due to headwinds

10:13 EST BridgeBio confirms Eidos cancellation of ATTRibute-PN study in ATTR-PN - BridgeBio has confirmed to The Fly that Eidos Therapeutics has canceled the ATTRibute-PN study, a Phase 3 study of the efficacy and safety of acoramidis in subjects with symptomatic Transthyretin Amyloid Polyneuropathy, or ATTR-PN. According to an update posted to the ClinicalTrials.gov website dated February 9, the recruitment status of the study is indicated to be "Withdrawn (Sponsor's decision to cancel study)." "We are focused on completing our ongoing ATTR-CM trial, which we continue to believe has promise for patients. We will also push forward additional high-quality programs in our pipeline. We still think that acoramidis could become an additional therapeutic option for people suffering with ATTR-PN, and we hope there will be a time for us to study it in that population. Within our means and as best as we can, we remain committed to the ATTR community in its broadest sense," Neil Kumar, the founder and CEO of BridgeBio, said in an emailed statement to The Fly.

10:05 EST Toyota Spain partners with LoJack Espana for stolen vehicle recovery service - Toyota Spain has partnered with LoJack Espana, a subsidiary of CalAmp, to offer an innovative service for the recovery of stolen vehicles. The agreement between Toyota Spain and LoJack Espana will give Toyota customers access to best-in-class stolen vehicle recovery services enabled by direct collaboration with local law enforcement. Through this agreement, the Official Dealer Network of Toyota Spain will market LoJack SVR services directly, through Toyota Custom, the Toyota Original Accessories program.

10:03 EST IZEA begins accepting Dogecoin, Litecoin, Shiba Inu, Crypto.com Coin - IZEA Worldwide announced that it now accepts Dogecoin, Litecoin, Shiba Inu and Crypto.com Coin as payments for its managed influencer marketing services. Influencers in select campaigns for which IZEA is paid in crypto can also choose to be paid in these cryptocurrencies. This expansion follows an announcement that Bitcoin and Ethereum are now accepted forms of payment.

10:01 EST Global Payments commences strategic review of Netspend consumer business - Earlier, along with its report of results for the fourth quarter, Global Payments CEO Jeff Sloan stated: "It has been an active period for capital management with more than $6 billion deployed since 2020 to expand our target addressable markets while concurrently returning capital to shareholders. Our free cash flow conversion and balance sheet provide us with ample firepower to continue to execute on our priorities At the same time, we seek to refine our portfolio mix by simplifying the composition of our businesses and maintaining a singular focus on our corporate customers. As part of that initiative, we have commenced a strategic review of the Netspend consumer business; we intend to retain its B2B assets as we further expand this new pillar of our strategy."

10:00 EST U.S. Xpress Enterprises falls -22.0% - U.S. Xpress Enterprises is down -22.0%, or -97c to $3.45.

10:00 EST Preferred Apartment rises 14.0% - Preferred Apartment is up 14.0%, or $2.51 to $20.47.

10:00 EST IronNet rises 29.0% - IronNet is up 29.0%, or $1.02 to $4.53.

09:52 EST Fluidigm Advanta Dx COVID-19 EASE Assay approved for emergency use - According to a letter dated February 7 that was posted to the site of the FDA, Fluidigm's Advanta Dx COVID-19 EASE Assay was granted Emergency Use Authorization for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab, mid-turbinate nasal swab, and anterior nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider. Reference Link

09:47 EST Canada Goose falls -19.9% - Canada Goose is down -19.9%, or -$6.82 to $27.49.

09:47 EST U.S. Xpress Enterprises falls -23.8% - U.S. Xpress Enterprises is down -23.8%, or -$1.05 to $3.37.

09:47 EST Bowlero rises 19.8% - Bowlero is up 19.8%, or $1.53 to $9.25.

09:44 EST Vistas Media Acquisition Company Inc trading resumes

09:39 EST Vistas Media Acquisition Company Inc trading halted, volatility trading pause

09:36 EST Fluence Energy Inc trading resumes

09:34 EST Vimeo trading halted, volatility trading pause

09:33 EST Sysorex plans to sell certain assets in exchange for equity - Sysorex announced that it plans to sell certain assets to another company in exchange for equity valued significantly higher than the Company's market capitalization. "Following Sysorex's reverse merger with TTM Digital Assets & Technologies, Inc. last year, Sysorex has experienced a substantial increase in gross revenue, and its prospects for future revenue generation and growth are solid. The Company has also increased its asset portfolio of GPUs, completed the acquisition of its datacenter, and closed a strategic investment in an NFT marketplace. Yet, our common stock continues to trade at prices well below the value the business actually holds. Therefore, we believe the best course of action is to advance this transaction, which is designed to unlock value for shareholders," said Wayne Wasserberg, chief executive officer of Sysorex. Sysorex, in making this announcement, notes that there can be no assurance that the anticipated transaction will result in a closing but expects that the transaction will close later this month or in early March.

09:31 EST Borqs Technologies says micro-electronics manufacturing line 'up and running' - Borqs Technologies provides the following updates on the Company's core business activities. The Company's micro-electronics manufacturing line at the Huzhou South Taihu New Area of Zhejiang Province is up and running with a capacity of 100,000 units per month. The current products being produced are smart control devices for use by utility companies in grid interactive water heater programs in the U.S. These devices will play an important role in smart cities in terms of energy savings. In Nov 2021, the Company reported that it has received $15 million of purchase orders from a reputable U.S. Fortune 500 Company to supply multiple models of enterprise Android based handheld computer products for the U.S., EU and Asian markets. Subject to the pending availability of components, may deliver up to 20% of the order by year end 2021, with the bulk to be completed by 1st half of 2022. As of December 31, 2021 the Company completed 20% of the $15 million purchase order from the Fortune 500 customer. The remaining balance of 80% of the order will be completed in the first two calendar quarters of 2022. The Company's solar energy storage business unit, Holu Hou Energy, has commenced the pilot phase of a large-scale solar project in Hawaii. While continuously growing its business presence in Hawaii, HHE's management team is evaluating the business opportunities in the continental U.S. market.

09:17 EST Matterport appoints Florence Shaffer as VP, strategy & operations - Matterport (MTTR) announced that it has appointed Florence Shaffer as Vice President, Strategy & Operations, Chief of Staff to CEO, and Deepti Illa as Vice President, Global Integrated Marketing. Shaffer will join Matterport's executive leadership team and report to CEO RJ Pittman, helping drive the company's strategic and operational mandate. Illa will report directly to recently named Chief Marketing Officer, Tom Klein. She will lead global marketing efforts to elevate the Matterport brand and scale adoption across all key vertical markets. Most recently, Shaffer held the dual position of Global Vice President, Technology Strategy & Operations and Chief of Staff to the Chief Innovation Officer at Estee Lauder Companies (EL). Illa joins Matterport from RingCentral (RNG), a leading provider of business cloud communications, where she held the position of Vice President of Marketing, leading the company's enterprise marketing that accounts for approximately half of its revenue.

09:13 EST Tomi Environmental receives multiple orders for Custom Engineered Systems - TOMI Environmental Solutions announced that it has received approximately $1.3M of orders for its Custom Engineered Systems and have set installation dates for these systems. Two of the orders are from a Fortune 500 pharmaceuticals company and the other is from a leading research facility focused on immunology and infectious disease. TOMI installed its first CES in 2016 for Dana Farber Cancer Institute and has installed an additional 6 units to date. The Company is seeing an increased pipeline of sales opportunities for the CES solution primarily due to higher numbers of cleanrooms being used by pharmaceutical and life science companies, as well as a shift from manual to automated disinfection to drive more efficiency and effectiveness. These customers choose TOMI's CES solution because it eliminates human error, provides accuracy unmatched by competing solutions and reduces labor cost and down time. Because TOMI's CES solution is a highly customized product, there is typically a longer lead time from sale to manufacture and final installation. Design and technical concepts tailored to the specific needs of each customer must be established prior to manufacturing. The Company expects to realize revenue from these orders in late 2022 and early 2023.

09:11 EST Diana Shipping announces time charter contracts for M/V Aliki, M/V Leonidas - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Koch Shipping Pte. Ltd., Singapore, for one of its Capesize dry bulk vessels, the m/v Aliki. The gross charter rate is US$24,500 per day, minus a 5% commission paid to third parties, for a period until minimum February 1, 2023 up to maximum April 15, 2023. The charter is expected to commence on February 19, 2022. The m/v Aliki is currently chartered, as previously announced, to Solebay Shipping Cape Company Limited, Hong Kong, at a gross charter rate of US$20,500 per day, minus a 5% commission paid to third parties. The "Aliki" is a 180,235 dwt Capesize dry bulk vessel built in 2005. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Cargill International S.A., Geneva, for one of its Kamsarmax dry bulk vessels, "Magnolia". The gross charter rate is US$24,500 per day, minus a 4.75% commission paid to third parties, for a period until minimum March 1, 2023 up to maximum April 30, 2023. The charter is expected to commence upon delivery of the vessel to the Company. As previously announced on July 16, 2021, the m/v Leonidas P. C. is a 2011 built Kamsarmax dry bulk vessel of 82,165 dwt that the Company entered into an agreement to purchase in July 2021. The vessel is now expected to be delivered to the Company by the sellers by mid-February 2022. The employments of "Aliki" and "Leonidas P. C." are anticipated to generate approximately $17.49M of gross revenue for the minimum scheduled period of the time charters.

09:08 EST Trex Company supports AEC Communicty with focused products, resources - To further elevate its profile within the AEC community, Trex has created a website and portfolio of products specifically geared toward these audiences. Trex.com/Professionals, which launched in mid-2021, houses digital content dedicated to satisfying the information and material needs of project specifiers and serves as a resource hub where professionals can access pertinent information about Trex's product offerings. Visitors will find the following information: company overview, product overview, projects/case studies, resources, BIM library, contact/support. "Since going live last July, the Trex Professionals site has served as a valuable resource for decision-makers across the architectural and landscape design arenas," said Leslie Adkins, vice president of marketing for Trex. "The real beauty of the site - and of working with Trex - is that specifiers can find everything they need to create an ultimate outdoor space all in one place and from one trusted, reliable, industry-leading source."

09:06 EST WynnBET online & mobile sportsbook launches in Louisiana - WynnBET, the online sports betting and casino app from Wynn Resorts, announced that its online sports betting platform is live in the state of Louisiana. Players in Louisiana can download the mobile app or visit https://la.wynnbet.com/sportsbook to begin wagering.

09:05 EST Arcimoto joins NavaIX SoCal Tech Bridge Project Vesta - Arcimoto announced that it has joined SoCal Tech Bridge's Project Vesta, a public-private partnership designed to mitigate wildfires using a combination of next-generation technologies, powered by AI, 5G, and ultra-efficient vehicles. In collaboration with TESIAC, Arcimoto will participate in the first Project Vesta live experiment from February 14 to 18 at Camp Roberts in San Miguel, CA. The Vesta Team will be testing an unmanned fire mitigation prototype that combines state-of-the-art technology to identify risk, reduce response time, and support wildfire mitigation efforts. "Fires start small, so the faster we can identify and locate a growing wildfire and deploy the appropriate tools, the more we can mitigate this growing problem, saving billions of dollars in damages to our forests and communities, while making the emergency safer for the boots on the ground," said Jesse Fittipaldi, Arcimoto Chief Strategy Officer. "The idea is elegant and simple, bringing together some of our most exciting technologies: use AI to scan the skies for smoke trails, dispatch fire-fighting drones and ultra-efficient vehicles using 5G connectivity to quickly arrive on the scene, buying valuable time for firefighters to arrive before a small fire has a chance to grow into a wildfire."

09:05 EST Pure Storage announces strategic engagement with Amazon Web Services - Pure Storage (PSTG) announced a strategic engagement with Amazon Web Services (AMZN) for solution development and enablement programs for Pure's Portworx solutions to help enterprises move Kubernetes workloads into production. As part of its work with AWS, Portworx has also announced an Early Access Program for Portworx Backup as-a-Service on AWS. Portworx BaaS introduces a modern data protection control plane to accelerate implementation of data and application recovery objectives, delivering speed and simplicity to application owners for safeguarding Kubernetes applications. Portworx BaaS is one of the many as-a-Service offerings the company will deliver to its customers in the future. This three year strategic engagement is the latest step in expanding the relationship between Pure Storage and AWS, and will deliver a comprehensive Kubernetes platform for mutual customers moving applications into production.

09:04 EST Covenant Logistics completes acquisition of AAT Carriers - On February 9, 2022, the Company completed an acquisition of AAT Carriers, Inc. headquartered in Chattanooga, TN that will become a part of Covenant's Expedited segment. The acquired business specializes in highly regulated, time-sensitive loads for the U.S. government. For 2021, the acquired business generated approximately $25 million in revenue. The purchase price includes a substantial earnout component based on the acquired business' adjusted earnings before interest, taxes, depreciation, and amortization reported for the first and second years following closing. The total purchase price, including any earnout achieved, is expected to range from $35 million to $55 million and represent between 3.3 and 5.5x Adjusted EBITDA depending on the results achieved by the acquired business. The transaction included a Code Section 338(h)(10) election and is expected to be immediately accretive to earnings per diluted share. David Parker, Chairman and CEO, commented "Today's announcements, along with the recent announcement of our first quarterly dividend, are consistent with our capital allocation strategy and commitment to delivering stockholder value. With visibility to a more consistent business model, we are focused on actively managing our balance sheet to provide growth and improve returns. Today's moves are exciting on both fronts. The acquisition offers attractive margins along with entry into a market with higher barriers to entry and less sensitivity to economic cycles than most expedited freight. While Expedited is not the primary focus of our growth efforts, this deal was attractive due to its projected cash flow profile and the opportunity to diversify our end markets and provide consistent miles for our team drivers. The stock repurchase program is intended to acquire shares when financially attractive and justified by our leverage profile. Based on our anticipated cash flows from operations and net capital expenditures, we expect to finish the year with a net leverage ratio of less than 1.0 to 1.0 after giving effect to this acquisition and assuming completion of the entire stock repurchase program. This outlook gives us confidence as we continue to review opportunities to deploy capital."

09:03 EST Tenable Technology Ecosystem reaches 100 partners, 200 unique integrations - Tenable announced its Technology Ecosystem has reached 100 partners and 200 unique integrations. "Available for free with all Tenable products, the expanded Ecosystem streamlines the vulnerability management process for customers by allowing them to integrate Tenable's visibility and insights with other security applications in their environment. In turn, they can enjoy enhanced visibility and automated workflows, and are able to manage credentials, correlate threats, remediate issues, enrich systems and more effectively secure the cloud," the company said.

09:02 EST Healis Therapeutics acquires ownership of key botulinum toxin patent from AbbVie - Healis Therapeutics, a privately held biotechnology company, announces its ownership of a key botulinum toxin patent from AbbVie. After clinically significant results in early trials, Allergan acquired the rights to develop botulinum toxin for depression in 2013. Allergan completed a Phase II study in 2017 and announced plans for Phase III. AbbVie assumed ownership through its 2020 acquisition of Allergan. Healis Therapeutics takes over the exclusive license from AbbVie to develop botulinum toxin as a potential treatment for Major Depressive Disorder.

08:57 EST NCL Corporation announces proposed offerings of senior secured notes - NCL Corporation announced that it is proposing to sell $1,000.0 million aggregate principal amount of its senior secured notes due 2027 and $600.0 million aggregate principal amount of its senior unsecured notes due 2029 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The Secured Notes and the related guarantees will be secured by first-priority interests in, among other things and subject to certain agreed security principles, three of our vessels. The Secured Notes will be guaranteed by our subsidiaries that own the property that will secure the Secured Notes. NCLC also announced today that it is proposing to sell $435.0 million aggregate principal amount of its exchangeable senior notes due 2027 in a private offering that is exempt from the registration requirements of the Securities Act. NCLC intends to grant the initial purchasers of the Exchangeable Notes an option to purchase, during a 13-day period beginning on, and including, the first day on which the Exchangeable Notes are issued, up to an additional $65.0 million aggregate principal amount of Exchangeable Notes. The Exchangeable Notes will be general senior unsecured obligations of NCLC and guaranteed by NCLH. Holders may exchange all or a portion of the Exchangeable Notes at the holder's option at any time prior to the close of business on the business day immediately preceding August 15, 2026, subject to the satisfaction of certain conditions and during certain periods, and on or after August 15, 2026 until the close of business on the business day immediately preceding the maturity date, regardless of whether such conditions have been met. Upon exchange of the Exchangeable Notes, NCLC will satisfy its exchange obligation by paying and/or delivering, as the case may be, cash, ordinary shares of NCLH or a combination of cash and ordinary shares, at NCLC's election. NCLC will pay any cash required to be paid upon exchange of the Exchangeable Notes. If NCLC elects to satisfy its exchange obligation solely in ordinary shares or in a combination of ordinary shares and cash, the Exchangeable Notes will convert into Series A Preference Shares of NCLC, which shall immediately and automatically be exchanged for a number of ordinary shares. NCLC intends to use the net proceeds from the Notes Offering and the Exchangeable Notes Offering to redeem all of the outstanding 12.25% Secured Notes and 10.250% Secured Notes and to make principal payments on debt maturing in the short-term, including, in each case, to pay any accrued and unpaid interest thereon, as well as related premiums, fees and expenses.

08:55 EST Markets on Main enters master distribution agreement with Amfluent - Global Technologies announced that its wholly owned subsidiary, Markets on Main has entered into a Master distribution Agreement and Marketing Management Agreement. On January 19, 2022, MOM entered into an Exclusive Distribution Agreement with Amfluent. Under the terms of the Distribution Agreement, MOM will become an exclusive distributor for the promotion and sale of products carried by Amfluent. As the exclusive distributor, MOM was awarded the exclusive territory of e-commerce, live shopping and digital sales. The Distribution Agreement has a term of one year from the Effective Date unless both parties agree to renew the Distribution Agreement for an additional term.On January 30, 2022, MOM entered into a Marketing Management Agreement with Chin Industries, Inc. Under the terms of the Marketing Agreement, Chin Industries will act as a consultant to manage the day-to-day operations of MOM's ecommerce websites. MOM's first product that it will act as the sole distributor under the Distribution Agreement with Amfluent is the Sculpt Baby Waist Wrap. The Sculpt Baby Waist Wrap has been featured on NBC, NUE GLOW, allure, Byrdie and others.

08:49 EST Vera Therapeutics announces pricing of upsized public offering of Class A stock - Vera Therapeutics announced the pricing of its public offering of 4,993,067 shares of its Class A common stock at a price to the public of $15.00 per share. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $74.9 million. All of the shares are being offered by Vera. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 748,959 shares of its Class A common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on February 14, 2022, subject to satisfaction of customary closing conditions. J.P. Morgan, Cowen, and Evercore ISI are acting as joint book-running managers for the offering.

08:44 EST Jaguar Health completes filing for FDA vet unit for Canalevia to treat dog EID - Jaguar Health, under its Jaguar Animal Health tradename for the veterinary market, announced that it has completed filing of the final major regulatory section with the U.S. Food and Drug Administration's Center for Veterinary Medicine to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia, crofelemer delayed-release tablets, to treat exercise-induced diarrhea, EID, in dogs. In December of 2021, Jaguar Animal Health received conditional approval from the FDA for Canalevia -CA1 for chemotherapy-induced diarrhea in dogs. "We are leveraging many of the same major technical sections from our successful CID submission for the proposed EID indication," said Dr. Michael Guy, DVM, MS, Ph.D., Jaguar Health's vice president of preclinical and nonclinical studies. "We expect that Canalevia could receive FDA conditional approval, under the name Canalevia -CA2, to treat EID in dogs in the fourth quarter of 2022."

08:40 EST Forbes and SPAC Magnum Opus announce Binance pact for Forbes to be listed - Forbes and Magnum Opus Acquisition Limited (OPA), a publicly traded special purpose acquisition company, announced a $200M strategic investment from cryptocurrency and blockchain infrastructure provider Binance. Forbes and Magnum Opus earlier announced plans to pursue a business combination, expected to close Q1 of 2022, through which Forbes would become a publicly traded company on the New York Stock Exchange trading under the ticker symbol (FRBS). Going public will enable Forbes to further capitalize on its successful digital transformation, using technology and data-driven insights to create more deeply engaged audiences, and associated high-quality and recurring revenue streams. Binance's strategic investment will be through Binance's assumption of subscription agreements representing $200M of commitments in the $400M private investment in public equity that was previously announced along with Forbes' intention to go public via a business combination with Magnum Opus. With Binance assuming existing PIPE commitments, the overall size of the PIPE will remain at $400M, and Binance's investment will be according to substantially the same terms as the existing PIPE investors. The transactions with Magnum Opus and Binance are expected to help Forbes maximize its brand and enterprise values and use its proprietary technology stack and analytics to convert readers into long-term, engaged customers of the platform, including through memberships and recurring subscriptions to premium content and highly targeted product offerings.

08:38 EST STRONG Technical Services completes projection system upgrade for Showplace - STRONG Technical Services completed the sale and installation of 38 projection systems for Showplace Entertainment. The sale and installation of equipment at Evansville North 9, Newburgh 10, and Evansville East 20 was completed in January 2022.

08:37 EST Schweitzer-Mauduit launches Botani hemp, botanical solutions business - Schweitzer-Mauduit International announced the launch of Botani, a premium hemp and botanical solutions business delivering innovative hemp wraps, fillers, and rolling/pre-roll papers to the natural fibers industry. Manufacturers who wish to accelerate the delivery of premium, elevated experiences to their customers will benefit from Botani's product research and development expertise acquired from over 400 years within the natural fiber, specialty paper and tobacco industries. Botani's product offerings include: Hemp Wrappers: Botani's hemp wrappers are self-adhering for blunt applications and moisture optimized for slow burning, safe storage, and an extended shelf-life. Hemp Fillers: Botani's hemp-based botanical products can be infused with active ingredients. Alternative product manufacturers can add Hemp Fillers to scale effectively in the rapidly growing pre-roll market or non-tobacco alternatives segment. Rolling and Pre-Roll Papers: Botani provides fully customizable Rolling and Pre-Roll papers to differentiate the brand experience using hemp and natural fibers.

08:35 EST Google Cloud chooses 3rd gen AMD EPYC processors - AMD (AMD) announced that AMD EPYC processors will power the new C2D virtual machine offering from Google Cloud (GOOG;GOOGL), "bringing customers strong performance and compute power for high-performance memory-bound workloads in areas like electronic design automation and computational fluid dynamics," the company said. With the help of AMD EPYC processors and its high core density, the C2D VMs will provide the largest VM sizes within compute optimized family at Google Cloud. As well, because of the EPYC processor's performance for compute focused workloads, Google Cloud showcased the C2D VMs can provide up to 30 percent better performance for targeted workloads compared to previous generation EPYC based VMs at a comparable size. "AMD EPYC processors continue to showcase their capabilities for HPC and compute focused workloads, whether running drug simulations for the latest vaccines, exploring the cosmos, or helping design critical hardware and electronics for the future of industry," said Lynn Comp, corporate vice president, Cloud Business, AMD. "The Google Cloud C2D instances with AMD EPYC processors will enable Google Cloud customers to run some of their most complex and intense workloads with ease, helping them design their products or solve complex problems, faster."

08:34 EST PepsiCo sees 'elevated' CapEx for 'another year or two' - Comments taken from Q4 earnings conference call.

08:32 EST HHT Global joins PHILUX Global Subfund for agriculture - PHI Group is pleased to announce that today HHT Global Co. Ltd., a Vietnamese limited liability company, has signed an agreement with PHI Group to join the PHILUX Global Subfund for agriculture. According to the agreement, HHT Global will contribute a mutually agreed amount of capital for the setup and initial operating budget of the subfund and hold 49% ownership of the general partners' portion of this fund. The main focus of this fund will be on agriculture in Vietnam. HHT Global and Empire Spirits, Inc., a subsidiary of PHI Group, Inc., will immediately cooperate to grow sorghum for Empire Spirits, Inc. and Five-Grain Treasure Spirits, a baiju distiller company with over one hundred years of tradition in Jilin Province, China.

08:31 EST T. Rowe Price reports preliminary AUM $1.58T at January 31 - Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $2.2B in January 2022. These client transfers include $1.9B transferred to the target-date retirement trusts during January.

08:26 EST UroGen data shows in-office nephrostomy tube Jelmyto administration 'efficient' - UroGen Pharma announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto,mitomycin, for pyelocalyceal solution administration in the Journal of Urology online on February 7, . This report provides a stepwise treatment approach to low-grade Upper Tract Urothelial Cancer from initial ureteroscopy to nephrostomy placement, Jelmyto administration, and eventual nephrostomy removal. "While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy," says Katie Murray, DO, Division of Urology, Department of Surgery, University of Missouri School of Medicine, Columbia, MO. "This report showed that antegrade instillation provided a well-tolerated and effective method of Jelmyto administration. In our experience we did not see a negative impact on patient comfort. Of note, our experience with antegrade administration in this analysis suggests that this approach, which minimizes manipulation of the ureter during instillation, may help protect against stricture formation which has been associated with repetitive instrumentation of the upper urinary tract. Given the potential benefits of antegrade versus retrograde administration of Jelmyto, we now have a replicable protocol to follow for antegrade administration using a nephrostomy tube." In both retrograde and antegrade approaches, Jelmyto can be administered as an outpatient procedure in the clinic. Retrograde administration requires administration by a physician via a ureteral catheter, requiring fluoroscopic guidance. Antegrade administration may be performed by trained nursing professionals under clean rather than sterile conditions and does not require fluoroscopy after a nephrostogram confirms placement at the first instillation.

08:18 EST Osisko Mining files technical report for Windfall mineral resource estimate - Osisko Mining announces that it has filed a technical report in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects to update the mineral resource estimate on its 100% owned Windfall gold deposit. The technical report entitled "Mineral Resource Estimate Update for the Windfall Project, Eeyou Istchee James Bay, Quebec, Canada" and dated February 10, 2022 has been prepared for Osisko by BBA.

08:17 EST Bigg Digital Assets announces C$9.8M investment in TerraZero - BIGG Digital Assets is pleased to announce a strategic investment of C$9.8 million in TerraZero Technologies for 14 million common shares, and 2 million warrants. This investment brings BIGG's total investment in TerraZero to C$10 million, and 14,650,000 shares, plus 2 million warrants. Through this investment BIGG now owns ~33% of TerraZero on a fully diluted basis. In connection with the investment into TerraZero, BIGG is entitled to appoint one member to TerraZero's board of directors; our board nominee is Lance Morginn. The company said, "BIGG believes the Metaverse is essential to the future of digital assets. The Metaverse is synonymous with NFTs, ERC-20 smart contracts, digital land, digital products and services, and meta-focused crypto assets. As BIGG continues to build a world class digital asset company, we believe TerraZero is the perfect fit. TerraZero Technologies' vision is to Develop, Acquire, and Finance the Metaverse's most promising companies, entrepreneurs, and developers. They build solutions to further enhance the Metaverse usability for greater community engagement, and to connect the real world to the Metaverse, for the creation of new economies and user experiences that will shape the future of web 3.0."

08:16 EST Ametek raises dividend 10% to 22c - Ametek announced its Board of Directors has approved a 10% increase in its quarterly cash dividend on common stock to 22c per share from 20c per share. The dividend is payable on March 31 to shareholders of record as of March 10. This dividend increase will raise the indicated annual rate to 88c per share.

08:14 EST Opiant Pharmaceuticals announces results from PK study for OPNT003 - Opiant Pharmaceuticals announced positive topline results from a multi-dose pharmacokinetic, PK, study for OPNT003, nasal nalmefene, an investigational treatment for opioid overdose. The crossover design study was conducted in 23 healthy subjects comparing the PK profile, safety, and tolerability of OPNT003 when given as a single 3mg dose in one nostril, as a single dose in each nostril, and as two doses in one nostril. Summary of topline results for OPNT003, nasal nalmefene: Demonstrated rapid nasal absorption in all three study arms; Showed dose proportional plasma concentrations whether administered as a single dose in each nostril or as two doses in a single nostril; Confirmed the long plasma half-life of nalmefene; Demonstrated nasal nalmefene is safe and well tolerated when administered in multiple doses; Opiant carried out the study at the request of the U.S. Food and Drug Administration and will include these data as part of its New Drug Application submission this year. "We are pleased that this study has met our objective of demonstrating safety, tolerability, and pharmacokinetic equivalence across multiple nasal doses," said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. "These data are fully consistent with the rapid delivery of high plasma concentrations of nalmefene observed in our previous OPNT003-PK-001 study, which compared 3 mg nasal nalmefene to a previously approved intramuscular dose. We look forward to completing our assessment of the potential of OPNT003 for treating opioid overdose with the ongoing pharmacodynamic study comparing nasal nalmefene with nasal naloxone."

08:13 EST Denali Therapeutics announces progress in DNL310 program - Denali Therapeutics announced that new longer-term data from an ongoing Phase 1/2 clinical trial of DNL310 are being presented today at WORLDSymposium. DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system and peripheral manifestations of MPS II. Phase 1/2 study data being presented at WORLDSymposium: The Phase 1/2 study data include longer-term biomarker data up to Weeks 49 and 24 from Cohort A and B, respectively; clinical outcomes data across Cohorts A and B at Week 24; and safety data up to Weeks 56 and 39 from Cohorts A and B, respectively. All patients have neuronopathic MPS II disease except for one patient with non-neuronopathic MPS II disease in Cohort B. Longer-term data demonstrate durability of CSF biomarker responses, now up to one year of dosing: Across Cohorts A and B, all patients had normalized levels of heparan sulfate in cerebrospinal fluid, CSF, by Week 24 of treatment with DNL310, which were sustained in all 5 patients from Cohort A at Week 49. Rapid response was observed in most patients after 4 to 6 weekly intravenous doses of DNL310, including in patients on lower dose regimens of DNL310. Exploratory CSF lysosomal lipid biomarker data showed further reductions with longer duration of treatment with DNL310, consistent with improved lysosomal function. Across Cohorts A and B, CSF GM3 ganglioside levels decreased from baseline, with normalized CSF GM3 ganglioside levels apparent in all 5 patients in Cohort A at Week 49, and in 9 of 12 patients in Cohort B at Week 24. Exploratory open-label clinical outcomes data, now including Cohort B, suggest improvements in the majority of patients: Exploratory clinical outcomes data at Week 24 from Cohort A, and now including Cohort B, suggest improved clinical symptoms and function in the majority of patients as reported by investigators and parents/caregivers. Safety profile of DNL310, now with over one year of dosing, remains consistent with standard-of-care: The safety profile of DNL310, which now includes data up to Weeks 56 and 39 from Cohorts A and B, respectively, remains consistent with standard-of-care enzyme replacement therapy. DNL310 was generally well tolerated with the most common treatment-emergent adverse events being infusion-related reactions, IRRs. IRRs occurred in 15 of 20 patients: the majority had mild or moderate IRRs, and 1 patient had severe IRRs. Most IRRs occurred during the first 12 study weeks. The study continues without modification following recommendation by an independent data monitoring committee in October 2021. Data continue to support initiation of a potentially registrational Phase 2/3 clinical trial of DNL310: Based on the strength of the clinical and preclinical data to date, Denali plans to initiate a potentially registrational Phase 2/3 trial with DNL310 with the goal of demonstrating efficacy and safety in participants with neuronopathic and non-neuronopathic MPS II.Key efficacy endpoints include: the effect of DNL310 on CSF biomarkers; the effect of DNL310 on neurobehavioral parameters; the effect of DNL310 on systemic manifestations of disease; and patient/caregiver reported outcomes. Dosing is expected to begin in the Phase 2/3 trial in the first half of 2022.

08:13 EST IronNet enters agreement with GCC on collective defense of insfrastructure - In a press release last night, IronNet "announced the execution of a multi-year contract with a Gulf Cooperation Council country -which is remaining anonymous to help protect its operational security-to enable it to better defend its most important governmental, financial, and infrastructure enterprises, country-wide, against cyber attacks. The GCC country will use IronNet's leading AI-based Network Detection and Response solution, as well as the IronNet Collective DefenseSM platform, to facilitate real-time, collaborative cyber defense spanning key ministries and enterprises, as well as between public and private organizations in an effort to more quickly detect vulnerabilities across critical industry and government sectors." Shares of IronNet are up 26% in pre-market trading at $4.42.

08:12 EST BriaCell provides update on insider buying - As disclosed December 16, 2021, certain members of BriaCell's Board of Directors and Management team had informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% of the Company's Common Shares and Listed Warrants outstanding within the six month period commencing January 31, 2022. Any Insider purchase will be conducted in compliance with the Company's insider trading policy and Insiders will meet the SEC and TSX reporting obligations. The timing and dollar amount of Insiders' purchases may vary individually. Purchases of securities by Insiders may coincide with BriaCell's ongoing Buyback. BriaCell has internal governance procedures in place to execute the Company's Buyback repurchases independently from any Insiders' purchase of Securities.

08:10 EST Alnylam gives FY22 product and revenue from collaborations and royalties view - Sees FY22 combined net product revenues for ONPATTRO, GIVLAARI, OXLUMO and vutrisiran $900M - $1,000M ; Net revenues from collaborations and royalties $175M - $225M. Consensus for FY22 revenue is $1.26B.

08:08 EST Cerence announces further details on partnership with Pioneer - Cerence announced further details of its previously announced partnership with Pioneer Corporation. Cerence will provide natural, conversational speech recognition in Pioneer's just-announced NP1, a connected, integrated hardware and software device that will bring personalized experiences to drivers in Japan. Designed to serve as a conversational driving partner mounted on the windshield, NP1 is equipped with an integrated front/rear camera and microphone/speaker system. With Cerence voice recognition and natural language understanding, NP1 enables drivers to navigate to their destination safely using only their voice and receive lane-by-lane directions spoken aloud. "It's important that all drivers have the ability to benefit from innovation and advancements in AI and voice technology that will enhance their in-car experience," said Stefan Ortmanns, CEO, Cerence. "We are proud to partner with Pioneer to bring natural, conversational speech recognition to drivers and enable a safer, more comfortable, and more productive experience while on the road." Pioneer's NP1 will be available in Japan in March 2022.

08:07 EST Breckenridge Distillery announces second series of 'Super' Sexy Motor Oil - Breckenridge Distillery announced the second release of their highly anticipated and limited-edition beer-barrel whiskey, 'Super' Sexy Motor Oil, for this Valentine's Day. Produced in collaboration with Breckenridge Brewery, series two of 'Super' Sexy Motor Oil brings the unique flavors of coffee and coconut. Breckenridge Distillery's 'Super' Sexy Motor Oil will be exclusively sold at their two locations only on Valentine's Day this year, releasing at 11 a.m.

08:06 EST Rigetti, Zapata announced new phase to long-standing partnership - Rigetti Holdings (RGTI) and Zapata Computing announced a new phase in their long-standing partnership: the companies are developing an industry-first compilation toolchain explicitly designed for hybrid quantum-classical algorithms. As part of the work, Zapata will integrate Orquestra, its unified platform for building and deploying quantum-ready applications at enterprise scale, directly with Rigetti's Quantum Cloud Services. The integration provides access to Rigetti QPUs, including the company's recently announced 80Q Aspen-M system. Specifically, this new collaborative effort aims to build a compiler stack that optimizes code for the feature sets of both the quantum and classical hardware within a hybrid loop. The companies expect the compilation toolchain to be available to Zapata customers and Rigetti Quantum Cloud Services users in Q2 2022. Rigetti announced in October it has entered into a definitive merger agreement with Supernova Partners Acquisition Company II (SNII), a publicly traded special purpose acquisition company.

08:05 EST Oracle, Telefonica partner to offer global cloud services - Oracle (ORCL) and Telefonica Tech (TEF) announced an agreement to jointly offer cloud platform-as-a-service and applications to enterprises and public sector organizations across Telefonica Tech's customer base. The services will be delivered through a global partnership which will enable Telefonica Tech to offer Oracle Cloud Infrastructure services as part of its portfolio as well as support clients through professional and managed services. To support the increasing demand for cloud services in Spain, Telefonica will also become the host partner for the Oracle Cloud Madrid Region. The new region will be designed to provide Spanish business and public sector customers with a broad and consistent set of cloud services with low latency, high performance, and the highest security standards. It will also help customers with business continuity and address their in-country data residency and compliance requirements. The Madrid region is Oracle's first cloud region in Spain, and one of at least 44 cloud regions Oracle plans to open by the end of 2022, continuing one of the fastest expansions of any major cloud provider.

08:04 EST Quoin Pharmaceuticals signs exclusive distribution agreement with ER-Kim - Quoin Pharmaceuticals announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe, for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure. Under the terms of the revenue sharing agreement, ER-Kim gains exclusive rights to commercialize QRX003 in fifteen countries throughout the CEE including Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czechia, Hungary, Kosovo, Moldova, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, and Slovenia. Quoin will be the exclusive supplier of QRX003 to ER-Kim.

08:03 EST Enphase Energy expands battery storage in Utah - Enphase Energy announced that Enphase installers in Utah have seen an increase in deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries, as more Utah residents seek protection against grid outages. "We're proud to call the Beehive State home, and we're proud to call Enphase our partner," said Matt Rasmussen, CEO at ION Solar, an Enphase Platinum installer. "Enphase Energy Systems, powered by sophisticated microinverter technology and paired with our end-to-end installation experience, offer Utah homeowners access to the future of energy independence and resilience today."

08:02 EST Kellogg: Q4 results negatively impacted by employee strike - Kellogg said in a statement: "The Company continued to face an unusually challenging business environment in the fourth quarter marked by a resurgence of COVID-19, persistent worldwide bottlenecks and shortages, and accelerating cost inflation. Its results were also negatively impacted by the strike of approximately 1,400 union employees at the Company's four U.S. cereal plants, which began in early October and ended in late December. While working through these challenging supply conditions, the Company also continued to largely offset market- driven cost inflation with productivity and revenue growth management efforts, while sustaining strong momentum in its international regions, and in its North America snacks business."

07:47 EST Ra Medical Systems awarded patent for support catheter by USPTO - Ra Medical Systems announces that on February 8, the USPTO granted the company a patent for a support catheter used with a small flexible liquid core catheter for laser ablation of arterial plaque blockages to restore blood flow. This is the 10th U.S. patent issued to Ra Medical and further strengthens protection of the company's novel liquid core ablation catheters. U.S. patent 11,241,519 B2, Small Flexible Liquid Core Catheter for Laser Ablation in Body Lumens and Methods for Use, describes a support catheter used in conjunction with the DABRA liquid core ablation catheter. Bench studies conducted by Ra Medical have demonstrated the utility of combining the DABRA ablation catheters with support catheters in navigating difficult peripheral vasculature.

07:47 EST Accuray reports data from phase III trial of TomoBreast - Accuray announced that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer. An analysis of patient reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy - a significant improvement above the 66.9% achieved with conventional radiotherapy. The single-center trial results were published online in BMC Cancer. The TomoTherapy platform, including the next-generation Radixact System, is the first in the world capable of helical radiation delivery.

07:38 EST Scynexis announces results from Phase 3 CANDLE study of ibrexafungerp - SCYNEXIS announced positive results from its global Phase 3 CANDLE study investigating the safety and efficacy of oral ibrexafungerp for prevention of recurrent vulvovaginal candidiasis, rVVC, also known as vaginal yeast infection. The Company plans to submit the results to the U.S. Food and Drug Administration in the first half of 2022 and anticipates receiving approval by year-end. The Phase 3 CANDLE study evaluated the efficacy and safety of oral ibrexafungerp compared to placebo in 260 female patients with rVVC, defined as three or more episodes of VVC in the previous 12 months. The study showed that 65.4% of patients receiving ibrexafungerp achieved clinical success by having no recurrence at all, either culture-proven, presumed or suspected, through Week 24 compared to 53.1% of placebo-treated patients. The advantage of ibrexafungerp over placebo was sustained over the three-month follow-up period and remained statistically significant. Secondary endpoints were consistent with the results of the primary analysis, and will be presented at a future medical meeting. In the study, ibrexafungerp was generally safe and well-tolerated.

07:36 EST Digital Ally hires Pettigrew as VP of Sports & Entertainment - Digital Ally announced that Bryan Pettigrew has been named Vice President, VP, of Sports & Entertainment and will work on business development for the company. Pettigrew will be based at the DGLY headquarters in Lenexa, KS and will work with newly acquired businesses, future business merger & acquisitions, as well as the company's sports properties in NASCAR, IndyCar Series and World of Outlaw. Pettigrew joins Digital Ally after serving as the Tournament Director for the PGA TOUR's Barbasol Championship.

07:35 EST OpGen announces successful completion of Unyvero A30 development milestone - OpGen announced that its subsidiary Curetis has successfully met a key milestone in the development of the new Unyvero A30 RQ platform instruments. Over the course of the last several months the A30 RQ instruments were put through a rigorous process of final verification and validation, V&V, testing. These tests were designed and conducted per the applicable guidelines and recommendations, including IEC 61010/UL 61010 for instrument safety, IEC 61326 for electromagnetic compatibility and interferences and EN 60086 for transport, storage and operational conditions. The performed V&V tests included testing of mechanical and electrical safety, radiated and conducted electrical emissions and interference, mechanical robustness when exposed to mechanical shock and vibration, heat, cold, humidity and other environmental factors. All these tests passed successfully. Oliver Schacht, CEO of OpGen indicated that "this success in meeting this final key milestone in the Unyvero A30 instrument development now enables us to move into final product design and to get a first set of series-ready instruments built. In parallel, we expect to work on our first A30 cartridge application and look forward to bringing the platform into its first clinical trial later in 2022. Such trial data would then be aimed at future regulatory submission and clearance by the U.S. Food and Drug Administration. Having the A30 ready for clinical trials and subsequent commercialization will also be key to any partnering and licensing conversations going forward."

07:33 EST Generation Bio promotes Antoinette Paone to COOO - Generation Bio announced the promotion of Antoinette Paone to chief operating officer, COO. Paone has served as senior vice president and head of regulatory affairs and quality at Generation Bio since 2018. "Antoinette has made significant contributions to shaping our strategic direction, and her leadership has also elevated our operational performance," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Antoinette will now lead operations more broadly, including an integrated CMC, quality, and regulatory team, to deliver the internal GMP capacity to enable our goal of bringing novel medicines to broad populations of people living with genetic diseases."

07:32 EST Rogers Sugar continues to expect improved financial performance in 2022 - The company said, "The health and safety of our employees remains our top priority. We are closely following all COVID-19 public health authority recommendations and have enhanced safety protocols in place. To date our plants have operated without any disruption during the COVID-19 pandemic; however, the uncertainty and increased demand volatility make it difficult to estimate the impact on future sale volumes, operations and financial results. We are closely monitoring the situation and will continue to adapt quickly to the changing circumstances. Despite lower than expected results in both of our segments in the first quarter, we remain optimistic for this year's results and we continue to expect improved financial performance in 2022 in both segments supported by stronger volume and improved margins in the next three quarters. We continue to expect the sugar segment to perform well in fiscal 2022. Underlying domestic demand remains strong across all customer segments supported by the renewal of key customer agreements and favourable pricing adjustments. In Taber, the harvest season delivered the expected volume of sugar beets; the processing campaign is going as expected and we anticipate completing the slicing of the crop by the end of February. The overall sugar production is expected to yield approximately 120,000 metric tons of beet sugar. Sales volume expectations remain unchanged and are expected to reach approximately 770,000 metric tonnes, representing a reduction of 9,500 metric tonnes compared to 2021. While we continue to anticipate the domestic volume to grow steadily at about 2%, export opportunities are not expected to be as strong as in 2021, resulting in a reduction in volume. Overall, we expect the following volumes variances for our customer segments: Industrial, our largest segment, is expected to grow at 1% as demand for sugar-containing products remains steady both in Canada and the US. Liquid volume is expected to deliver growth of approximately 2% to 3% driven by continued demand from existing customers. Consumer volume is also expected to grow by 1%, a level aligned with the normalized growth we experienced pre-covid. We anticipate selling less in the export markets in 2022, due to a less favourable market dynamics for high-tier sales. Despite the reduction of total volume, favourable price adjustments are expected to improve profitability as compared to 2021. Maintenance programs for the Montreal and Vancouver operating facilities are expected to follow the trend of previous years and are expected to result in a marginal increase in operating costs. For the Taber facility, a return to normal and an improvement in the quality of the sugar beet over 2021 is expected to yield improvement in operating costs. Distribution costs are expected to increase overall by 5% to 10%, reflecting a higher market price for warehousing, rails and ground transportation. Spending on capital projects is also expected to be similar to recent periods. For fiscal 2022, we anticipate spending approximately $25.0 million on various capital projects, with approximately a quarter allocated to return-on-investment projects. For fiscal 2022, we continue to expect the Maple business segment to outperform our 2021 results, largely driven by improved sales margins, despite the lag in passing through increased costs experienced during the current quarter. We anticipate increased margin from new agreements negotiated with new and existing customers and volume to remain stable at approximately 52 million pounds. In addition, we expect to continue to drive lower operating costs through ongoing optimization at our manufacturing facilities and efficiency improvements provided by the investments made in our facilities at Granby and Degelis. Capital investments have been reduced significantly for the Maple segment since 2021, considering the expenditures incurred over the past few years that improved and increased our production capacity. We continue to expect steady growth in demand for Maple-related products, although we expect a tempering from the increase seen during the period of COVID-19."

07:29 EST Manchester United announces multi-year kit partnership with Tezos - Manchester United announced a multi-year partnership which will see Tezos featured on the club's range of men's and women's training kits. Tezos-branded training kit will be worn by the first team squad for the first time prior to this weekend's match against Southampton, introducing Manchester United fans to the partnership and Web3 technology through the Tezos blockchain.

07:28 EST Lazard reports preliminary AUM approximately $258.7B as of January 31 - The month's AUM included market depreciation of $9.5B, net outflows of $4.1B and foreign exchange depreciation of $1.5B.

07:27 EST Bombardier says on track to meet 2025 objectives - 2022 outlook expected to outperform 2021 and is on track to meet 2025 objectives: the company anticipates delivering more than 120 units, exceeding $6.5B in revenues, increasing adjusted EBITDA by 29% compared to 2021 to greater than $825M, increasing adjusted EBIT to greater than $375M, and achieving more than $50M of positive free cash flow.

07:19 EST Else Nutrition appoints Carlos Lifschitz to scientific advisory board - ELSE NUTRITION HOLDINGS is pleased to announce that Dr. Carlos Lifschitz has joined Else Nutrition's Scientific Advisory Board. Dr. Lifschitz is the Associate Physician at the Italian Hospital, Buenos Aires, Argentina and former Associate Professor at Baylor College of Medicine, Houston, Texas, USA.

07:17 EST PepsiCo: Global SodaStream business delivered over $1B in net revenue in 2021

07:16 EST Tiziana Life Sciences to present at annual BIO CEO & Investor conference - Tiziana Life Sciences announced that Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th. Management will be available for 1x1 investor meetings on February 14-15. Register here to request a meeting with management. Presentation Focus: Tiziana is developing proprietary and novel formulation technologies to enable alternative routes of immunotherapy. Tiziana's lead programs are focused on developing the fully-human antibody, foralumab via varied modes of delivery, alone or in combination to address different therapeutic indications. Data from clinical and animal studies support the underlying hypothesis that nasally administered foralumab acts via site-targeted immunomodulation. This concept was further validated by clinical data from a recently completed study with nasally administered foralumab in COVID-19 patients. Further, interim data from a clinical study in a patient with secondary progressive multiple sclerosis also indicated that the treatment was not only well-tolerated, but it also produced clinical response after three months of treatment. Consequently, the Food and Drug Administration reviewed the safety data and allowed continuation of dosing. Six-month treatment results in this patient will be reported in the first quarter of 2022. A similar mechanism of site-targeted immunomodulation exists for orally administered foralumab for treatment of inflammatory bowel diseases such as Crohn's Disease and ulcerative colitis. Recently, Tiziana submitted an amended Investigational Drug Application for a Phase 1b study evaluating safety and tolerability of orally administered foralumab in patients with mild-to-moderate Crohn's Disease. The study is expected to conclude in the fourth quarter of this year.

07:15 EST Gilat Satellite chosen by Intelsat for its new SkyEdge IV platform - Gilat Satellite Networks announced that Intelsat completed a strategic selection process and placed a significant initial order for Gilat's new SkyEdge IV platform, which will be used for its latest high throughput satellite, Intelsat IS-40e, designed to augment inflight connectivity and mobile backhaul services over North America. Gilat's Elastix-TotalNMS will support Intelsat's current and future satellites to orchestrate network management of a unified network. "We are honored that our valued partner, Intelsat, made a strategic decision to adopt Gilat's next generation SkyEdge IV platform. The SkyEdge IV platform, VSATs, and network management system are optimized to support both current HTS and future very high throughput software-defined satellites and thus meet Intelsat's demanding needs," said Amir Yafe, VP of Mobility & Global Accounts at Gilat. "Gilat's SkyEdge IV is a multi-orbit, multi-service platform built to lead the satcom industry's next generation, known as the Elastix Era, supporting cloud infrastructure, an Elastix-Access Scheme, and working in harmony with software-defined satellites."

07:14 EST Diebold names Octavio Marquez as CEO - Diebold Nixdorf announced that the board of directors has appointed Octavio Marquez as the company's president and CEO effective March 11. Marquez will also join Diebold Nixdorf's board. Current CEO Gerrard Schmid will remain a member of the board of directors until his current term expires at the 2022 Annual Shareholder Meeting and will serve as an advisor to the company to help ensure a seamless transition. Marquez, current executive vice president of Global Banking, joined Diebold in January 2014 and has held multiple leadership roles during his time at the company.

07:13 EST Credit Suisse sees Equities revenue impacted by Prime Services exit - Credit Suisse said: "Compared to the exceptional levels of 1Q21, we have seen a reversion to lower, pre-pandemic levels of business activity, particularly given the monetary tightening that central banks have initiated. We also expect our Equities revenues to be impacted by the exit from Prime Services. However, after a weak start to the year, we are seeing encouraging signs of improving franchise momentum, including positive net new asset inflows year-to-date in our Wealth Management business."

07:12 EST IsoPlexis announces publication of study on its immune monitoring platform - IsoPlexis announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as Post-Acute Sequelae of COVID-19, PASC, or Long COVID. In the paper, titled "Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae," researchers correlated patient symptoms with in-depth profiling of blood cells and plasma components throughout COVID-19 infection to identify factors associated with the development of PASC. Using IsoPlexis' single-cell functional proteomics platform, the researchers were able to identify correlations between the enhanced presence of certain polyfunctional immune cell types and the presentation of inflammation associated with PASC: Increased frequency of "supervillain" T cell subsets is positively associated with certain PASC symptoms/conditions, or endotypes, and disease severity at convalescence. Similarly, presence of "supervillain" monocytes in convalescent patients compared to healthy subjects is correlated with all of the major PASC endotypes, indicating the impact of monocytes on a sustained inflammation at convalescence. Natural killer cells in PASC endotypes played less of an active role in convalescence inflammation of PASC.

07:10 EST Twitter up 9% after earnings, buyback announcement - Twitter shares are up $3.31, or 9%, to $41.14 in pre-market trading.

07:10 EST Interpublic increases dividend from 27c to 29c, $400M share repurchase program - Interpublic Group announced that the company's Board of Directors has declared a quarterly dividend on IPG common stock of 29c per share, payable on March 15, 2022, to holders of record at the close of business on March 1, 2022. The increase in the dividend from 27c to 29c per share represents a seven percent increase to the Company's quarterly dividend. Additionally, the company's Board of Directors authorized a resumption of the company's share repurchase program. Under the reauthorized program, the company may repurchase, from time to time, up to $400M of IPG common stock. Philippe Krakowsky, CEO of IPG, commented, "We are very pleased to announce our company's tenth consecutive year of higher dividends, which have continued through the period of the COVID pandemic, and the resumption of our share repurchase program. These actions reflect the continuing strength of our operating results. We had suspended share repurchases following our announcement of the Acxiom transaction in 2018 as we focused more of our resources on financial deleveraging. As we resume our share repurchase program, we plan to continue our commitment to operating in a manner that will maintain and enhance our balance sheet and financial flexibility."

07:07 EST Descartes Systems announces it has acquired NetCHB for $40M - Descartes Systems Group announced that it has acquired NetCHB, a leading provider of customs filing solutions in the US. NetCHB's cloud-based platform is used by more than 700 customs brokers to connect to the US Customs and Border Protection Automated Broker Interface to electronically execute both fiscal customs declarations and security filings. "As the digitization of the logistics and supply chain industry picks up pace, we continue invest in complementary solutions that add depth and breadth to our Global Logistics Network," said Edward Ryan, Descartes' CEO. "NetCHB has a team of deep customs domain experts, scalable and robust technology solutions, and a large group of customers that will benefit from additional solutions available on the GLN to help them manage the lifecycle of shipments." Descartes acquired NetCHB for up-front cash consideration of $40M, plus potential performance-based consideration. The maximum amount payable under the all-cash performance-based earn-out is $60M, based on NetCHB achieving revenue-based targets over the first two years post-acquisition.

07:06 EST MediWound announces additional $9M in funding from BARDA - MediWound announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has expanded its awarded contract with MediWound by providing supplemental funding of $9 million to support the NexoBrid BLA resubmission with the U.S. Food and Drug Administration and the ongoing expanded access treatment protocol. MediWound was awarded its first BARDA contract for treatment of thermal burn injuries in 2015. That first BARDA contract, valued at up to $168 million, supported advanced development and manufacturing, as well as the procurement of NexoBrid as a medical countermeasure as part of U.S. preparedness for mass casualty events. Under that first BARDA contract, BARDA provided technical assistance and a total of up to $91 million for NexoBrid development activities needed to request U.S. marketing approval from the FDA. These activities include the NexoBrid Phase 3 study and subsequent requirements for BLA resubmission, the ongoing Phase 3 pediatric study and the NexoBrid expanded access treatment protocol. In January 2020, BARDA committed an additional $16.5 million to procure NexoBrid as part of the HHS mission to build national preparedness for public health medical emergencies. The contract further includes a $10 million option to fund development of other potential NexoBrid indications, and an option to procure additional NexoBrid valued at up to $50 million. In addition to that first BARDA contract, BARDA also has a separate contract with MediWound to support the development of NexoBrid as a debridement product to treat sulfur mustard injuries. The cumulative, non-dilutive funding under both contracts with BARDA is now valued at up to $211 million. As of December 31, 2021, the company has received approximately $70 million in funding, in the aggregate, from BARDA under the two contracts to support development activities and an additional $14.6 million for procurement of NexoBrid for U.S. emergency preparedness.

07:03 EST Twitter reports Q4 average mDAU was 217M, up from 211M in prior qaurter - Twitter reports average mDAU was 217 million for Q4, compared to 192 million in the same period of the previous year and compared to 211 million in the previous quarter. Average U.S. mDAU was 38 million for Q4, compared to 37 million in the same period of the previous year and compared to 37 million in the previous quarter. Average international mDAU was 179 million for Q4, compared to 155 million in the same period of the previous year and compared to 174 million in the previous quarter.

07:02 EST AstraZeneca board to increase annualized dividend by 10c to $2.90 - Reflecting increased confidence in future growth and cash generation, the Board intends to increase the annualized dividend by 10c to $2.90, and has approved a second interim dividend for FY 2021 of $1.97, payable in March 2022. This results in a total dividend declared for FY 2021 of $2.87.

06:48 EST Charah Solutions awarded ash marketing contract by western utility - Charah Solutions announced that it has been awarded a fly ash sales and marketing contract from a western utility for the sustainable recycling of fly ash from its plant. Charah Solutions will be responsible for the beneficiation and utilization of the specification grade fly ash. The fly ash will be distributed through Charah Solutions' MultiSource materials network, a unique distribution system of nearly 40 nationwide locations, with international sourcing and distribution, which provides a continuous and reliable supply of supplementary cementitious materials to cement and concrete producers to make "green concrete" as well as other customers who beneficially reuse the products. It is anticipated that 100% of the fly ash will be shipped by rail to markets on the west coast.

06:40 EST BitNile unit to install EV chargers in Bel Air shopping center - BitNile Holdings announced that its green energy technology and power supply subsidiary, TurnOnGreen, has partnered with The Glen Centre, in Los Angeles, Calif. to expand the property's electric vehicle charging capabilities for its thousands of annual visitors. The electrification project is expected to be complete by March 2022 and will feature TurnOnGreen's commercial network level 2 charger, the EVP700G, installed in the main parking lot. Drivers will be able to locate the chargers using the TurnOnGreen mobile application and initiate a charging session with the app, QR code, or RFID card. The TurnOnGreen mobile application is available for download on the App Store for iPhone users and Google Play for Android users.

06:32 EST Credit Suisse sees 2022 as a 'transition' year - Credit Suisse said: "As previously highlighted at our Investor Day on November 4, 2021, the year 2022 will be a transition year for Credit Suisse as the benefits of our strategic capital reallocation towards core businesses and generating structural costs savings to invest for growth should largely materialize from 2023 onwards. In this context, the results for 2022 are expected to be adversely affected by restructuring costs and higher compensation costs compared to last year. Our reported results are expected to also reflect volatility in the share price of our 8.6% holding in Allfunds Group. During 2022, we intend to meet our goal of releasing a cumulative $3B of allocated capital from our Investment Bank for reinvestment into Wealth Management and other core businesses."

06:27 EST Watts Water sees FY22 organic growth 3%-8%, adj. operating margin 14.3%-14.7% - Sees adjusted margin flat to up 40bps, with free cash flow 90%+ of net income. Sees FY CapEx $45M, with an adjusted effective tax rate of about 25%.

06:15 EST Precision Drilling anticipates higher demand for its services - The company said, "The return of global energy demand and the need for global upstream oil and natural gas investment has resulted in sustained periods of strong commodity prices, providing a promising backdrop for the oilfield services industry. At current commodity prices, we anticipate higher demand for our services and improved fleet utilization as customers look to maintain and replenish production levels as drilled but uncompleted well inventories have been depleted and offset the impact of a multi-year period of upstream underinvestment. Interest in our EverGreen environmental solutions continues to gain momentum as customers seek meaningful solutions to achieve their emission reduction targets and improve their well economics. We expect our growing suite of Alpha digital technologies paired with our EverGreen environmental solutions to be key competitive differentiators as our predictable and repeatable drilling results deliver exceptional value to our customers by reducing risks, time, well construction costs, and carbon footprint. The Government of Canada's $1.7B well site abandonment and rehabilitation program has supplemented industry activity levels and provided thousands of jobs throughout Western Canada. The program runs through to the end of 2022 with government funds provided in stages. Our well servicing business continues to capture opportunities because of our scale, operational performance, and strong safety record. During the Q4 of 2021, our abandonment activity remained strong, and we expect this momentum to continue through to the end of the program in 2022. During 2020, the Government of Canada introduced the CEWS program to subsidize a portion of employee wages for Canadian employers whose businesses have been adversely affected by COVID-19. The CEWS program ended in the fourth quarter of 2021. For the three months ended December 31, 2021, we recognized C$300,000 in CEWS program assistance, which was presented as offsets to operating and general and administrative expenses of $200,000 and $100,000, respectively."

06:10 EST PepsiCo raises annualized dividend 7% to $4.60 per share from $4.30 - The company announced a 7% increase in its annualized dividend to $4.60 per share from $4.30 per share, effective with the dividend expected to be paid in June 2022. This represents the company's 50th consecutive annual dividend per share increase.

06:04 EST Allot Ltd. selected by telecom operator in Southeast Asia for cybersecurity - Allot announced that a telecom operator in Southeast Asia, in a deal signed toward the end of 2021, has selected the Allot Secure unified family of solutions to provide cybersecurity protection to its small and medium-sized business, or SMB, customers. The operator and Allot will share recurring revenues generated by monthly service fees.

05:44 EST Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA - Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application, or sBLA, for Dupixent as an add-on maintenance treatment for children aged six months to five years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The target action date for the FDA decision on this investigational use is June 9, 2022. Dupixent remains the only biologic medicine approved for patients six years of age and older in this indication.

05:35 EST Vir Biotechnology says preclinical data suggests sotrovimab neutralizes omicron - Vir Biotechnology announced that preclinical data suggest that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the United States and developed in conjunction with GlaxoSmithKline, retains neutralizing activity against the BA.2 subvariant of omicron. These pseudovirus results are being shared with government and regulatory authorities around the world and the company expects to publish data on bioRxiv in the coming week, with live virus data to follow.

05:26 EST TotalEnergies to purchase SunPower CIS business for $250M - TotalEnergies (TTE) announced it has signed a definitive agreement with SunPower's (SPWR) to purchase its commercial and industrial solutions, or CIS, business for $250M, including $60M of earn-out, subject to regulatory evolution. TotalEnergies is the majority shareholder of SunPower. It will allow TotalEnergies to extend its distributed generation business footprint to the U.S. and to develop over 100 MW of additional capacity per year. Following a process involving discussions with a number of parties, and upon the unanimous recommendation of a special committee of SunPower's independent directors, the acquisition has been approved by both companies. The transaction is expected to close early Q2 subject to the satisfaction of customary closing conditions. This operation is not expected to reduce TotalEnergies' majority ownership stake in SunPower.

05:19 EST Genetron announces companion diagnostic collaboration with Hutchmed - Genetron (GTH) announced that it has signed a collaboration agreement with Hutchmed (HCM) for the joint development of a companion diagnostic, or CDx, test for Orpathys in China. Under the agreement, the partners plan to jointly validate and register Genetron Health's approved NGS-based 8-gene Lung Cancer Assay as CDx for Orpathys. Developed based on Genetron Health's proprietary One-step Seq method, the 8-gene Lung Cancer Assay was approved by China's National Medical Products Administration, or NMPA, as an IVD assay in 2020. This assay is the first approved NGS-based panel for non-small cell lung cancer, or NSCLC, on the market that could detect RNA-based MET exon 14 skipping alterations for therapy selection and monitoring. The assay has been commercialized in China for use in hospitals and has also obtained CE Mark in 2021.